0000000000524342

AUTHOR

Thorsten Meyer

showing 3 related works from this author

Zum spezifischen Versorgungsbeitrag psychosozialer Krebsberatungsstellen – Sichtweisen der Ratsuchenden und Zuweisenden

2021

Ziel Ziel der Studie ist es, den spezifischen Versorgungsbeitrag von Krebsberatungsstellen (KBS) sowohl aus Sicht der Ratsuchenden wie aus Sicht der Zuweisenden in den Blick zu nehmen. Methodik Qualitatives Design mittels leitfadengestutzter face-to-face-Interviews mit Krebspatient/innen/Angehorigen und telefonischer Einzelinterviews mit Zuweisenden. Ergebnisse Insgesamt wurden 43 Ratsuchende und 30 Zuweisende befragt. In Bezug auf die Beratungsinhalte werden die psychoonkologische Begleitung und Hilfe zur Selbsthilfe in Kombination mit einer sozialrechtlichen Aufklarung uber zusatzliche Unterstutzungsleistungen als zentrale Merkmale wahrgenommen. In der Gruppe der Zuweisenden scheint jedoc…

03 medical and health sciencesPsychiatry and Mental healthClinical Psychology0302 clinical medicine030220 oncology & carcinogenesis05 social sciences0501 psychology and cognitive sciences050108 psychoanalysisApplied PsychologyPPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie
researchProduct

Synthesis and pharmacological characterization of beta2-adrenergic agonist enantiomers: zilpaterol.

2009

The beta-adrenergic agonist 1 (zilpaterol) is used as production enhancer in cattle. Binding experiments of separated enantiomers on recombinant human beta(2)-adrenergic and mu-opioid receptors and functional studies showed that the (-)-1 enantiomer accounts for essentially all the beta(2)-adrenergic agonist activity and that it exhibits less affinity toward the mu-opioid receptor than (+)-1, which is a mu-opioid receptor antagonist. X-ray crystallography revealed the absolute configuration of (-)-1 to be 6R,7R.

AgonistTrimethylsilyl CompoundsStereochemistrymedicine.drug_classZilpaterolAbsolute configurationBiological activityStereoisomerismPharmacologyAdrenergic beta-AgonistsReceptor antagonistCrystallography X-RayRecombinant Proteinschemistry.chemical_compoundchemistryDrug DiscoverymedicineMolecular MedicineHumansEnantiomerReceptorBeta (finance)Adrenergic beta-2 Receptor AgonistsChromatography High Pressure LiquidJournal of medicinal chemistry
researchProduct

Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment.

2009

Background Praziquantel (PZQ) is the drug compound of choice in the control and treatment of schistosomiasis. PZQ is administered as a racemate, i. e. 1∶1 mixture of enantiomers. The schistosomicidal activity arises from one PZQ-enantiomer, whereas the other enantiomer does not contribute to the activity. The WHO's Special Programme for Research and Training in Tropical Diseases (TDR) has assigned the low-cost preparation of pure schistosomicidal (−)-PZQ a key priority for future R&D on PZQ, but so far this transition has not happened. PZQ has two major administration drawbacks, the first being the high dose needed, and its well documented bitter and disgusting taste. Attempts of taste-mask…

Tastelcsh:Arctic medicine. Tropical medicine(R)-Praziquantellcsh:RC955-962Pediatrics and Child HealthSchistosomiasisPharmacologyBiologyCrystallography X-RayPraziquantelDrug compoundSchistosomicidesmedicineHumansSchistosomiasisChildChemistry/Organic ChemistryInfectious Diseases/Helminth InfectionsMolecular Structurelcsh:Public aspects of medicinePublic Health Environmental and Occupational HealthDrug administrationlcsh:RA1-1270Stereoisomerismmedicine.diseaseBitter tastePraziquantelInfectious DiseasesInfectious Diseases/Neglected Tropical DiseasesTastemedicine.drugResearch ArticlePLoS neglected tropical diseases
researchProduct